Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have received an average recommendation of “Hold” from the twelve analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $27.50.
NVRO has been the subject of a number of recent research reports. JMP Securities cut their target price on Nevro from $75.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, August 2nd. Robert W. Baird cut their price objective on shares of Nevro from $26.00 to $23.00 and set a “neutral” rating for the company in a research report on Wednesday, August 2nd. Oppenheimer cut their price target on shares of Nevro from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, August 2nd. Truist Financial cut their price target on shares of Nevro from $18.50 to $17.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Finally, Canaccord Genuity Group cut their target price on Nevro from $68.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, August 2nd.
Institutional Inflows and Outflows
Nevro Stock Performance
NYSE NVRO opened at $16.58 on Tuesday. The company has a market cap of $600.36 million, a PE ratio of -5.80 and a beta of 0.88. The stock’s 50 day simple moving average is $17.40 and its 200-day simple moving average is $21.50. Nevro has a 1-year low of $13.98 and a 1-year high of $48.10. The company has a debt-to-equity ratio of 0.66, a current ratio of 6.55 and a quick ratio of 5.01.
Nevro (NYSE:NVRO – Get Free Report) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.12. Nevro had a negative net margin of 24.22% and a negative return on equity of 33.99%. The business had revenue of $103.86 million during the quarter, compared to analysts’ expectations of $95.87 million. During the same period in the prior year, the business earned ($0.62) earnings per share. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Nevro will post -2.83 EPS for the current fiscal year.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems.
- Five stocks we like better than Nevro
- What is Forex and How Does it Work?
- Safeguard your portfolio with these three bargain stocks
- What Are Defense Contractor Stocks? How to Invest in Defense
- Membership clubs gain leverage for the consumer rebound
- Conference Calls and Individual Investors
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.